The Hospital Clínic starts an immunotherapy trial based on tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1